XR 311
Alternative Names: HN 66000; KSB 311M; KSB 311N; KSB 311P; KSB 311R; PEP04; Project KSB311R; SOT-107; TF CRM 107; Transferrin-CRM 107; TransMID; TransMID 107M; TransMID 107N; TransMID 107P; TransMID 107RLatest Information Update: 02 Apr 2024
At a glance
- Originator GE Healthcare; National Institutes of Health (USA)
- Developer Nxera Pharma; Nycomed; Xenova Group
- Class Antineoplastics; Drug conjugates; Immunotoxins
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued CNS cancer; Glioblastoma; Glioma